Phenotype and Clinical Outcomes of Titin Cardiomyopathy. by Tayal, Upasana et al.
Tayal, U; Newsome, S; Buchan, R; Whiffin, N; Halliday, B; Lota, A;
Roberts, A; Baksi, AJ; Voges, I; Midwinter, W; Wilk, A; Govind,
R; Walsh, R; Daubeney, P; Jarman, JWE; Baruah, R; Frenneaux,
M; Barton, PJ; Pennell, D; Ware, JS; Prasad, SK; Cook, SA (2017)
Phenotype and Clinical Outcomes of Titin Cardiomyopathy. Journal
of the American College of Cardiology, 70 (18). pp. 2264-2274. ISSN
0735-1097 DOI: https://doi.org/10.1016/j.jacc.2017.08.063
Downloaded from: http://researchonline.lshtm.ac.uk/4609933/
DOI: 10.1016/j.jacc.2017.08.063
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Phenotype and Clinical Outcomes of
Titin Cardiomyopathy
Upasana Tayal, BMBCH,a,b Simon Newsome, MSC,c Rachel Buchan, MSC,a,b Nicola Whifﬁn, PHD,a,b,d
Brian Halliday, MBCHB, MRCP,a,b Amrit Lota, BMBCH,a,b Angharad Roberts, MBBS, PHD,b A. John Baksi, PHD,a,b
Inga Voges, MD,b Will Midwinter, BSC,b Alijca Wilk, BSC,b Risha Govind, MSC,b Roddy Walsh, MSC,a,b
Piers Daubeney, DM,b Julian W.E. Jarman, MBBS, MD(RES),b Resham Baruah, MBBS, BSC, PHD,b
Michael Frenneaux, MD,a,b Paul J. Barton, PHD,a,b Dudley Pennell, MD,b James S. Ware, PHD,a,b,d
Sanjay K. Prasad, MD,a,b Stuart A. Cook, PHDa,b,d,e,f
ABSTRACT
BACKGROUND Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help
guide patient stratiﬁcation.
OBJECTIVES The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and
outcomes in DCM.
METHODS In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium
enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for
the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events.
RESULTS Of 716 subjects recruited (mean age 53.5  14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart
Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs.
54.1 years; p ¼ 0.002) and had lower indexed left ventricular mass (5.1 g/m2 reduction; padjusted ¼ 0.03) compared with
patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtvþ/ groups. Overall, 78
of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years),
including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite
primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv
(hazard ratio adjusted for primary endpoint: 0.92 [95% conﬁdence interval: 0.45 to 1.87]; p ¼ 0.82).
CONCLUSIONS In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that
prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be
associated with worse medium-term prognosis. (J Am Coll Cardiol 2017;70:2264–74) © 2017 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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D ilated cardiomyopathy (DCM) affects up tow1 in 250 individuals (1) and is the leadingglobal cause of heart transplantation (2,3).
Despite improvements in pharmacological and
device-based therapy, clinical outcomes in DCM
remain poor, with a 20% 5-year mortality rate (4,5).
As such, there is a pressing need for better mecha-
nistic understanding, improved risk stratiﬁcation,
and identiﬁcation of novel therapeutic targets for
DCM.
Recently, truncating variants in the gene for the
sarcomeric protein titin (TTNtv) have been identiﬁed
as the largest single genetic cause of DCM, found in
10% to 20% of cases (6,7). However, their phenotypic
and clinical signiﬁcance remains unclear, as the
presence and extent of phenotypic and outcome dif-
ferences in DCM patients with and without TTNtv
varies between studies (6–9).
Our aim in this study was to deﬁne the genotype-
phenotype correlation of TTNtv and how this was
associated with clinical outcome compared with DCM
patients without TTNtv.
METHODS
STUDY POPULATION. The study population
comprised 716 patients with DCM conﬁrmed by late
gadolinium enhancement (LGE) cardiovascular mag-
netic resonance (CMR) who were prospectively
enrolled in the National Institute for Health Research
(NIHR) Royal Brompton Hospital Cardiovascular Bio-
bank project between 2009 and 2015.
This cohort consisted of consecutive referrals to
the CMR unit from the dedicated cardiomyopathy
service at Royal Brompton Hospital, London, and a
network of 30 regional hospitals. Patients were
referred for diagnostic evaluation, family screening,
or assessment of DCM severity. Within the cardio-
myopathy service, all patients without contraindica-
tion undergo CMR at presentation. The majority of
patients underwent CMR (and were enrolled) at initial
diagnosis (n ¼ 381; 53.2%). Of the remainder, 81% (270
of 335) had been diagnosed <2 years before enroll-
ment and CMR conﬁrmation of DCM. All patients
provided written informed consent. The study was
approved by the regional ethics committee.
DIAGNOSIS OF DCM. DCM was diagnosed based on
established CMR criteria of left ventricular dilation
and reduced ejection fraction with reference to
age- and sex-adjusted nomograms (10) in the absence
of known coronary artery disease (presence of sub-
endocardial LGE suggestive of previous myocardial
infarction, >50% stenosis in 1 or more major
epicardial coronary arteries, or need for pre-
vious percutaneous coronary intervention or
coronary artery bypass grafting), abnormal
loading conditions (uncontrolled hyperten-
sion or signiﬁcant primary valvular disease),
or toxin exposure (alcohol consumption in
excess of 80 g/day for 5 years meeting criteria
for alcoholic cardiomyopathy). A history of
well-controlled hypertension or diabetes was
documented as comorbidities. A history of
any previous chemotherapy was docu-
mented. A history of alcohol excess above U.K. gov-
ernment guidelines was documented (21 units/week
for men; 14 units/week for women). Although pa-
tients with coronary artery disease were excluded, a
small proportion of patients had evidence of
concomitant myocardial infarction (n ¼ 17; 2.4%).
CLINICAL DATA. Baseline demographic and clinical
information was collected for all patients using pa-
tient interview, clinical records, electrocardiogram,
and family pedigree data. A family history of DCM
(DCM in the proband plus at least 1 other family
member) (11) or sudden cardiac death (in at least 1
family member up to third-degree relative) (12) was
recorded. A history of atrial or ventricular arrhythmia
prior to enrollment was documented as previously
described (13). Conduction disease was recorded in
the presence of any degree of heart block.
CARDIAC MAGNETIC RESONANCE. All patients un-
derwent CMR at 1.5-T (Siemens Sonata or Avanto
scanners, Siemens Medical Systems, Erlangen, Ger-
many). Breath-hold steady-state free precession cine
images were acquired in 3 long-axis planes and short-
axis slices as previously described (5). LGE images
were acquired using a breath-hold inversion recovery
sequence following administration of 0.1 mmol/kg of
gadolinium contrast agent (Magnevist or Gadovist,
Bayer, Leverkusen, Germany) as previously described
(5). Left ventricular (LV) volumes, function, and mass
were measured using a semiautomated threshold-
based technique (CMRtools, Cardiovascular Imaging
Solutions, London, United Kingdom). Maximum left
atrial (LA) volumes were assessed from the 2- and
4-chamber views at ventricular end-systole (14). All
volume andmassmeasurements were indexed to body
surface area and referenced to age- and sex-based ta-
bles (10). All CMR measurements were performed by
operators blinded to genetic and outcome data.
GENETIC SEQUENCING, VARIANT ANALYSIS, AND
CONFIRMATION. All patients underwent targeted
next-generation sequencing on Illumina or Life
Technologies 5500XL platforms using the TruSight
SEE PAGE 2275
AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiovascular magnetic
resonance
DCM = dilated cardiomyopathy
LGE = late gadolinium
enhancement
LMNA = lamin A/C gene
LVMi = indexed left ventricular
mass
TTNtv = truncating variant in
titin gene
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Cardio Sequencing kit (Illumina, San Diego, Califor-
nia) (15) or a custom SureSelectXT (Agilent, Santa
Clara, California) target capture with equivalent
content. Targeted deoxyribonucleic acid libraries
were prepared according to the manufacturers’ pro-
tocols. Variants were annotated and ﬁltered as pre-
viously described (Online Appendix) (6). Further
sequencing metric ﬁlters were applied including a
minimum coverage $10, QualbyDepth score >4, and
allelic balance $0.20.
Truncating variants were deﬁned as nonsense,
frameshift, or essential splice site variants. All TTNtv
variants were annotated to the titin meta-transcript
(ENST00000589042, LRG_391_t1) (Online Table 1).
Only rare TTNtv (minor allele frequency in the ExAC
[Exome Aggregation Consortium] dataset <0.0001) in
constitutively expressed cardiac exons were analyzed
(percentage spliced in: >90%) (6). All variants were
conﬁrmed with Sanger sequencing or by review of
mapped reads in Integrative Genomics Viewer.
For sensitivity analysis, rare (minor allele
frequency <0.0001) protein-altering variants (trun-
cating and nontruncating) in the gene-encoding nu-
clear envelope protein lamin A/C (LMNA) were
identiﬁed.
CLINICAL ENDPOINTS. The primary endpoint was a
composite of cardiovascular mortality, major
arrhythmic events, and major heart failure events.
Major arrhythmic events comprised hemodynamically
stable and unstable sustained ventricular tachycardia,
ventricular ﬁbrillation, appropriate implantable
cardiac-deﬁbrillator shock, and aborted sudden car-
diac death. Major heart failure events comprised heart
transplantation, LV assist device implantation, and
unplanned heart failure hospitalization.
Cardiovascular mortality and each of the
arrhythmic and heart failure composites were
pre-deﬁned secondary endpoints. Endpoints were
deﬁned according to the 2014 American College of
Cardiology/American Heart Association deﬁnitions
FIGURE 1 Position of TTNtv Variants According to Protein Domains and PSI
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Orange indicates Z disc; blue indicates I band; green indicates A band; and purple indicates M line. DCM ¼ dilated cardiomyopathy;
PSI ¼ percentage spliced in; TTNtv ¼ truncating variants in the titin gene.
TABLE 1 Baseline Demographics in DCM Patients Stratiﬁed by TTNtv Status
TTNtv Absent
(n ¼ 633)
TTNtv Present
(n ¼ 83) p Value
Age at baseline, yrs 54.1  14.3 49.0  13.5 0.002
Male 410 (64.8) 59 (71.1) 0.27
Caucasian 533 (84.2) 75 (90.4) 0.39
Family history of DCM 87 (13.7) 26 (31.3) <0.001
Family history of sudden cardiac death 95 (15.0) 12 (14.5) 1.0
History of peripartum cardiomyopathy 6 (0.9) 1 (1.2) 0.58
History of chemotherapy 32 (5.1) 2 (2.4) 0.41
History of moderate alcohol excess* 98 (15.5) 13 (15.7) 1.0
NYHA functional class† 0.17
1 261 (43.1) 39 (49.4)
2 245 (40.4) 32 (40.5)
3 94 (15.5) 6 (7.6)
4 6 (1.0) 2 (2.5)
Hypertension 203 (32.1) 10 (12.0) <0.001
Diabetes mellitus 79 (12.5) 8 (9.6) 0.57
Beta-blocker use 444 (70.1) 60 (72.3) 0.80
ACE inhibitor or ARB use 503 (79.5) 64 (77.1) 0.67
Aldosterone antagonist use 226 (35.7) 31 (37.3) 0.81
Diuretic use 287 (45.3) 41 (49.4) 0.49
Conduction disease 217 (34.3) 18 (21.7) 0.03
Left bundle branch block 179 (28.5) 8 (9.8) <0.001
History of atrial ﬁbrillation 140 (22.1) 23 (27.7) 0.27
History of nonsustained ventricular tachycardia 67 (10.6) 16 (19.3) 0.03
History of sustained ventricular tachycardia 14 (2.2) 1 (1.2) 1.0
Age is summarized as mean  SD and compared with the Mann-Whitney test. The remaining categorical variables
are summarized as n (%) and compared using the Fisher exact test. *Patients with a history of alcohol con-
sumption in excess of the U.K. government weekly “sensible limits.” Patients meeting criteria for alcoholic
cardiomyopathy were excluded from the cohort. †Missing data in 31 patients (4.3%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; DCM ¼ dilated cardiomyopathy;
NYHA ¼ New York Heart Association; TTNtv ¼ truncating variants in the titin gene.
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for cardiovascular endpoints in clinical trials (16) and
the 2006 American College of Cardiology/American
Heart Association/European Society of Cardiology
guidelines for management of patients with ventric-
ular arrhythmias (17), and are described in detail in
Online Table 2.
FOLLOW-UP DATA COLLECTION AND ADJUDICA-
TION. Follow-up data was collected from primary
and hospital care records and patient questionnaires.
Survival status was also identiﬁed using the U.K.
Health and Social Care Information Service to ensure
that no deaths were missed. Death certiﬁcates and
post-mortem reports were obtained where applicable.
All primary endpoint events were adjudicated by an
independent committee of 3 senior cardiologists
(J.J., R.B., M.F.) with expertise in electrophysiology,
heart failure management, and clinical trial adjudi-
cation, who were blinded to imaging and genetic
data. Follow-up time was truncated at 10 years given
the reduced number of individuals with follow-up
beyond 10 years.
STATISTICAL ANALYSIS. Continuous normally
distributed data are expressed as mean  SD, and
non-normally distributed data as median and inter-
quartile range (IQR). Continuous variables were
compared using the Mann-Whitney test. Categorical
data are expressed as number and percentages, and
compared using the Fisher exact test. Multivariable
linear regression analysis was used to evaluate pre-
dictors of LV mass and LV ejection fraction.
Outcome analysis was conducted on the subset of
patients (n ¼ 604) who were recruited to the study
prior to December 31, 2014, to allow at least 1 year of
follow-up time for all recruited subjects. For the
survival analysis, event-free survival was calculated
from the date of study entry to the date of the ﬁrst
event in the composite endpoint. Data for all patients
who were last known to be alive, or who had died
after December 31, 2015, were censored on December
31, 2015.
The Kaplan-Meier method was used to estimate
cumulative freedom from each endpoint, and the log-
rank statistic was used to test the null hypothesis that
there was no difference between groups in the prob-
ability of an event at any time point.
An optimized baseline model predicting the pri-
mary endpoint was built using Cox proportional
hazard modelling evaluating clinical and de-
mographic variables (Online Appendix and Online
Table 8). The primary analysis was to evaluate
association of TTNtv with the primary endpoint, on
univariable and multivariable analysis.
All statistical analyses were conducted in the
R environment, version 3.3.1 (R Foundation for
Statistical Computing, Vienna, Austria). Anonymized
data from participants who consented to data sharing
will be made available to researchers through request
to the corresponding author.
RESULTS
BASELINE CHARACTERISTICS. The ﬁnal study pop-
ulation consisted of 716 patients with a clinical and
imaging diagnosis of DCM conﬁrmed by CMR. There
were 469 men (65.5%), and the majority of the cohort
was Caucasian (n ¼ 608; 84.9%). Mean age at
recruitment was 53.5  14.3 years (range 11.5 to 88.4
years). The majority of patients were in New York
Heart Association functional class I (n ¼ 300; 41.9%)
or II (n ¼ 277; 38.7%) at enrollment, reﬂecting the
ambulatory status of the patients in this cohort. A
summary of demographics, clinical factors and base-
line medication is shown in Online Table 3.
Imaging characteristics of the DCM cohort are
shown in Online Figure 1 and Online Table 4. Overall,
mean left ventricular ejection fraction (LVEF) was
39.0  12.5% (median 40%; IQR: 30% to 49%). In line
with other DCM cohorts, midwall myocardial ﬁbrosis,
detected through LGE-CMR, was found in 250 (34.9%)
TABLE 2 Baseline CMR Variables in DCM Cohort Stratiﬁed by TTNtv Status
TTNtv Absent
(n ¼ 633)
TTNtv Present
(n ¼ 83) p Value
LV ejection fraction, % 40.0 (30.0–49.0) 39.0 (27.0–49.0) 0.48
Indexed LV end-diastolic volume, ml/m2 118.5 (103.5–143.8) 111.1 (100.6–136.4) 0.14
Indexed LV end-systolic volume, ml/m2 68.9 (53.8–96.7) 67.4 (51.0–100.1) 0.52
Indexed LV stroke volume, ml/m2 47.8 (13.3) 43.6 (12.8) 0.007
Indexed LV mass, g/m2 87.4 (73.6–106.5) 81.3 (69.4–96.8) 0.02
RV ejection fraction, % 54.0 (44.0–61.0) 53.0 (44.0–62.0) 0.65
Indexed RV end-diastolic volume, ml/m2 84.7 (70.5–101.8) 84.9 (70.1–99.4) 0.61
Indexed RV end-systolic volume, ml/m2 40.0 (28.8–53.0) 41.0 (28.0–51.5) 0.96
Indexed RV stroke volume, ml/m2 44.2  12.7 41.7  13.1 0.10
Indexed left atrial volume, ml/m2 54.1 (43.9–68.4) 57.2 (42.4–70.6) 0.79
Maximum LV wall thickness, mm 10.0  2.2 8.8  1.8 <0.001
Mean septal wall thickness, mm 7.9  1.9 7.2  1.5 0.002
Mean lateral wall thickness, mm 5.6  1.6 5.0  1.2 0.001
Midwall late gadolinium enhancement 224 (35.4) 26 (31.3) 0.54
Bystander myocardial infarction
(in patients with normal coronary
artery status)
16 (2.5) 1 (1.2) 0.62
Mitral regurgitation 0.48
None 340 (53.7) 49 (59.0)
Mild 210 (33.2) 23 (27.7)
Moderate 66 (10.4) 11 (13.3)
Severe 15 (2.4) 0 (0.0)
Values are median (interquartile range), n (%), or mean  SD. Between group comparisons were made using
Mann-Whitney or Fisher exact test as appropriate.
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricular; RV ¼ right ventricular; other abbreviations as in
Table 1.
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patients—mainly localized in the septum (n ¼ 188;
75.2%) (Online Table 4).
CURATION OF TITIN TRUNCATING VARIANTS.
TTNtv in constitutively expressed cardiac exons were
found in 83 patients (11.6%). The variants are listed in
Online Table 5. The position of the TTNtv and protein
domains is shown in Figure 1.
TTNtv CARDIOMYOPATHY PHENOTYPE. Patients
with TTNtv were younger at study recruitment
compared with patients without TTNtv (49.0 years vs.
54.1 years; p ¼ 0.002). There was no signiﬁcant dif-
ference in sex (p ¼ 0.27) or ethnicity (p ¼ 0.39) be-
tween groups (Table 1). As expected for a genetic
disorder, patients with TTNtv were more likely to
have a family history of DCM (Table 1). Amongst the
TTNtv patients with a family history of DCM (n ¼ 26),
22 in this cohort were probands and 4 were affected
family members. There was no difference in the fre-
quency of a family history of sudden cardiac death
between groups (Table 1). There was a lower inci-
dence of left bundle branch block (LBBB) at baseline
in patients with TTNtv compared with patients
without TTNtv (Table 1).
There was no signiﬁcant difference in biventricular
ejection fraction in patients with and without TTNtv
(median LVEF TTNþ/: 39.0% [IQR: 27.0% to 49.0%]
vs. 40.0% [IQR: 30.0% to 49.0%]; p ¼ 0.48; median
RVEF TTNþ/: 53.0% [IQR: 44.0% to 62.0%] vs. 54.0%
[IQR: 44.0% to 61.0%]; p ¼ 0.65) (Table 2). There were
no signiﬁcant differences in RV stroke volume or
cardiac chamber dimensions (left and right ventricu-
lar volumes or left atrial volume) between patients
with TTNtv and patients without TTNtv (Table 2).
Patients with TTNtv had a minor reduction in indexed
LV stroke volume compared with patients without
TTNtv (median TTNtvþ/ 43.6 ml/m2 vs. 47.8 ml/m2;
p ¼ 0.007).
Notably, patients with TTNtv had thinner LV walls
(mean maximum LV wall thickness TTNtv ¼ 10.0 
2.2 mm; TTNtvþ ¼ 8.8  1.8 mm); p < 0.001) and lower
indexed left ventricular mass (LVMi) (mean LVMi
TTNtv ¼ 87.4  26.4 g/m2; TTNtvþ ¼ 81.3  19.6 g/m2;
p ¼ 0.02) in the absence of statistically signiﬁcant
FIGURE 2 LV Hypertrophy in TTNtv DCM
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Beeswarm and boxplot (black bars indicate median, pink shaded boxes indicate interquartile range) of indexed left ventricular (LV) mass,
mean septal wall thickness (WT), and indexed LV end-diastolic volume (LVEDVi) stratiﬁed by titin status, showing that patients with TTNtv
have lower indexed LV mass and thinner LV walls in the absence of evidence of differences in LV dilatation. Between-group comparisons are
made using the Mann-Whitney test. NEG ¼ negative; POS ¼ positive; other abbreviations as in Figure 1.
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differences in indexed LV end-diastolic volume (mean
TTNtv¼ 127.7 35.8ml/m2,TTNtvþ¼ 122.5 34.5ml/m2;
p ¼ 0.14), compared with patients without TTNtv
(Figure 2, Table 2).
Typically, LVMi increases in line with increasing
indexed LV end-diastolic volume, but this effect is
reduced in TTNtv DCM (increase in LVMi per 1-ml/m2
increase in indexed LV end-diastolic volume: 0.26
g/m2 for patients with TTNtv, 0.42 g/m2 for patients
without TTNtv; p ¼ 0.006) (Figure 3). However, pa-
tients with TTNtv were less likely to have a history of
hypertension (12.0% vs. 32.1%; p < 0.001) (Table 1);
therefore, a linear regression analysis was performed
to evaluate predictors of LV mass.
A baseline regression model predicting LV mass
was built as outlined in the Online Appendix and
Online Table 9. On univariable linear regression
analysis, the presence of TTNtv was associated with a
7.8-g/m2 reduction in LVMi (95% conﬁdence
interval: 13.7 to 1.8 g/m2; p ¼ 0.01). On multivari-
able analysis, TTNtv was associated with lower LVMi
after adjusting for the covariates in the baseline
model, including hypertension, with an estimated
5.1-g/m2 lower LVMi (adjusted p ¼ 0.03) (Table 3).
There was no signiﬁcant difference in the pattern
of late gadolinium enhancement seen in DCM pa-
tients with TTNtv compared with patients without
TTNtv. Speciﬁcally, there was no signiﬁcant differ-
ence in the presence or location of LV midwall
ﬁbrosis, an important prognostic marker detected in
one-third of cases with DCM (Table 2).
POSITIONAL EFFECTS OF TTNtv ON CARDIAC
ENDOPHENOTYPES. Given that TTNtv variant loca-
tion has previously been suggested to inﬂuence
phenotype in a small cohort (n ¼ 42; of which 36 pa-
tients are included in this cohort) (6), we explored
this further in this larger cohort. On univariable
analysis of TTNtv and LVEF, RVEF, LVMi, and
biventricular volumes, there was no signiﬁcant rela-
tionship between TTNtv location and severity of the
cardiac phenotype (Figure 4).
CLINICAL OUTCOMES IN DCM. In total, 604 patients
were followed up for a median of 3.9 years (IQR: 2.0 to
5.8 years). A total of 78 patients (12.9%) met the
primary composite endpoint, with 24 (4.0%) cardio-
vascular deaths, 24 (4.0%) patients meeting the
arrhythmic secondary endpoint, and 50 (8.3%) pa-
tients meeting the heart failure secondary endpoint
(Online Tables 6 and 7).
A baseline Cox model predicting the primary
outcome was built as outlined in the Online
Appendix. The ﬁnal baseline model predicting the
primary endpoint consisted of LVEF, presence of
midwall ﬁbrosis LGE, indexed left atrial volume, and
sustained ventricular tachycardia (Table 4).
TITIN AND CLINICAL OUTCOMES: PRIMARY
ENDPOINT. Of the 604 patients in the outcome
cohort, 71 patients had TTNtv (11.8%). Of these, 9
patients (12.7%) with TTNtv met the primary
endpoint compared with 69 of 533 patients (12.9%)
without TTNtv. Survival curves comparing the
freedom from the primary endpoint for patients with
and without TTNtv are shown in Figure 5.
On univariable Cox proportional hazard modelling,
the presence of a TTNtv has a hazard ratio (HR) of 0.81
(95% conﬁdence interval: 0.41 to 1.63; p ¼ 0.56) for
the primary endpoint. On multivariable analysis
(adjusting for variables in Table 4), the presence of a
TTNtv was not associated with the primary endpoint
(HR: 0.92; 95% conﬁdence interval: 0.45 to 1.87;
p ¼ 0.82). Therefore, in this cohort, there was no
evidence to suggest that TTNtv was a signiﬁcant
prognostic indicator.
TITIN AND CLINICAL OUTCOMES: SECONDARY
ENDPOINTS. There was no signiﬁcant difference
between TTNtvþ and TTNtv DCM patients for the
FIGURE 3 Relationship Between LVMi and LVEDVi in Patients With and Without TTNtv
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Orange circles are patients with TTNtv. Blue circles are patients without TTNtv. The
regression slope of indexed left ventricular mass (LVMi) w LVEDVi (LVMi increase per
1-ml/m2 increase in LVEDVi) is shown for patients with TTNtv (orange line: 0.26g/m2) and
without TTNtv (blue line: 0.42g/m2). Typically, LVMi increases in line with increasing
LVEDVi, but this effect is reduced in TTNtv DCM (p ¼ 0.006). Abbreviations as in
Figures 1 and 2.
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secondary arrhythmic and heart failure endpoints
and cardiovascular mortality (Online Figure 2).
SENSITIVITY ANALYSIS: LMNA VARIANTS. Currently,
LMNA variants are the only clinically actionable DCM
genetic variants; therefore, sensitivity analysis was
performed after exclusion of 8 patients with rare
variants in LMNA, of whom 4 met the primary
endpoint. The results from the unadjusted and
adjusted HR for TTNtv on the primary endpoint were
very similar (unadjusted HR: 0.85; p ¼ 0.64; adjusted
HR: 0.92; p ¼ 0.83).
DISCUSSION
In this study of 716 patients with DCM, we combined
TTN sequencing with detailed cardiac phenotyping
using CMR to deﬁne genotype–phenotype correla-
tions and their associations with outcomes in TTNtv
cardiomyopathy. As the commonest genetic cause of
DCM (1,6,7), improved understanding of the clinical
manifestations of TTNtv cardiomyopathy offers scope
for reﬁned patient stratiﬁcation by genotype.
We demonstrate that DCM due to TTNtv is associ-
ated with a blunted hypertrophic response, high-
lighting possible disease mechanisms. We show that
TTNtv DCM has a similar adverse event proﬁle to non–
TTNtv DCM (Central Illustration). This data may help
inform clinical management in DCM. Finally, this
study highlights an improvement in DCM outcomes
overall when compared with previous registry and
study data (5,18,19).
NOVEL INSIGHTS INTO THE TTNtv PHENOTYPE. In
this study, we ﬁnd that the functional cardiac
phenotype in DCM patients with TTNtv is equivalent
to that of patients without TTNtv, albeit that TTNtv
DCM is associated with a lower LVMi.
Previous work from our group in a small allelic
series of TTNtv DCM cases (n ¼ 42) showed that the
TTNtv that affected the protein distally toward the
Cʹ terminus were associated with more severe car-
diac endophenotypes. A recent zebraﬁsh study
identiﬁed an internal promoter in the distal I band
(just before exon 240) for a short titin isoform,
named Cronos, that is active in mouse and human
hearts and, when disrupted, resulted in a severe
phenotype (20). In this study, we demonstrated
that the cardiac phenotype of TTNtv is not
accounted for by variant position, including Cronos
disruption.
We did, however, ﬁnd that TTNtv DCM is associated
with thinner LV walls and lower LV mass in the
absence of evidence of signiﬁcant differences in LV
dilation. This effect remained after controlling for
important clinical covariables. Although the magni-
tude of difference in wall thickness and LV mass are
not clinically informative and cannot be used to pre-
dict genotype based on phenotype, they may offer a
potential insight into the pathogenesis of TTNtv DCM.
At the sarcomeric level, titin plays a key role in the
mechanotransductive response of the cardiomyocyte
and regulation of cardiac hypertrophy. Pathological
hypertrophy and ventricular dilation and dysfunction
develop in response to biological stressors, such as
neurohormonal activation or myocyte injury. Patho-
logical hypertrophy is thought to develop from an
adaptive compensatory response to a maladaptive
state (21). Themammalian target of rapamycin (mTOR)
is an evolutionary conserved kinase that can modulate
cardiac hypertrophy (22), and increased mTORC1
signaling is an adaptive response to cardiac stress in rat
models. We have recently shown that rats with TTNtv
had elevated mTORC1 signaling at baseline but were
not able to increase signaling when stressed (23). This
may offer a biological explanation for the blunted hy-
pertrophic response observed in human TTNtv DCM,
although the mechanistic link between TTNtv and
mTORC activation remains to be established.
PREVALENCE OF TTNtv IN DCM. The prevalence of
TTNtv in this cohort (w12%) is lower than in previous
studies, which showed a prevalence of up to 25% in
familial DCM cases (7). However, TTNtv frequency
ranged from w8% to 40% across the 3 clinical cohorts
in the study by Herman et al. (7), with the highest
frequencies observed in patients evaluated for cardiac
TABLE 3 Linear Regression Analysis Evaluating Predictors of Left Ventricular Mass
Unadjusted Analysis Adjusted Analysis
Estimated Change
in LVMi (g/m2)
95% Conﬁdence
Interval p Value
Estimated Change
in LVMi (g/m2)
95% Conﬁdence
Interval p Value
Male 17.7 13.9 to 21.5 <0.0001 12.7 9.5 to 15.8 <0.0001
History of hypertension 6.8 2.7 to 11.0 0.001 7.6 4.3 to 10.8 <0.0001
LVEDVi (per 1-ml/m2) 0.42 0.37 to 0.46 <0.0001 0.39 0.34 to 0.43 <0.0001
Presence of TTNtv 7.8 13.7 to 1.8 5.1 9.7 to 0.4 0.03
LVEDVi ¼ indexed left ventricular end-diastolic volume; LVMi ¼ indexed left ventricular mass; TTNtv ¼ truncating variants in the titin gene.
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transplantation or with severely impaired function.
Therefore, it is plausible that TTNtv are enriched in
severe/end-stage DCM cohorts, and the prevalence of
w12% that we observe is a more accurate reﬂection of
the frequency of TTNtv in an unselected and ambulant
DCM population. This is supported by the 14% fre-
quency of TTNtv observed in an independent cohort of
DCM patients referred for clinical genetic testing (24).
TTN AND SEX. Previous studies have reported
conﬂicting outcomes for TTNtv DCM stratiﬁed by sex
(6–9). In our cohort of TTNtv DCM patients, 73%
were male. The sex distribution is interesting
because DCM is known to have a 3:1 male to female
ratio; yet, one might expect an autosomal domi-
nantly inherited genetic form of DCM to have a 1:1
male to female ratio. This suggests that additional
factors (modiﬁers) may be important for the devel-
opment of phenotype (penetrance) in individuals
with TTNtv and that the presence of TTNtv alone
may not be sufﬁcient.
CLINICAL OUTCOMES IN TTNtv CARDIOMYOPATHY. An
important aspect of the clinical management of DCM
FIGURE 4 Relationship Between TTNtv Location and Cardiac Endophenotypes Assessed by CMR in the Cohort
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The TTNtv location, deﬁned by the complementary deoxyribonucleic acid (cDNA) position, is plotted on the x-axis (units ¼ base pairs). A regression line with
95% conﬁdence intervals is shown for each variable, and the slope and p value of the regression is shown above each plot. Only variants in constitutive exons are
plotted. The dashed lines indicate the expected position of the Cronos promoter (upstream of exon 240, numbered according to the LRG391_t1 meta-transcript).
CMR ¼ cardiovascular magnetic resonance; LVEF ¼ left ventricular ejection fraction; LVESVi ¼ left ventricular indexed end-systolic volume; LVSVi ¼ left ventricular
indexed stroke volume; RVEDVi ¼ right ventricular indexed end-diastolic volume; RVEF ¼ right ventricular ejection fraction; RVESVi ¼ right ventricular indexed end-
systolic volume; RVSVi ¼ right ventricular indexed stroke volume; other abbreviations as in Figures 1 to 3.
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is the early identiﬁcation of the at-risk patient. We
have shown previously that patients with TTNtv have
a w3-fold increased odds of developing early atrial
and ventricular arrhythmias compared with patients
without TTNtv, highlighting how genetic information
may play a role in risk stratiﬁcation of patients with
DCM (13). In this study, we do not detect an increased
risk of long-term arrhythmic events on follow-up in
patients with TTNtv DCM compared to those without.
However, this ﬁnding may reﬂect an overall low
arrhythmic risk in our cohort that has relatively mild
disease. Future studies focusing on subpopulations of
DCM with a higher risk of arrhythmia are therefore
required to more fully elucidate a potential
interaction.
We did not identify any difference in the presence
of LV midwall ﬁbrosis, a marker of adverse outcome
in DCM (5), between TTNtvþ and TTNtv groups. In
this cohort, LGE was an independent predictor of
outcome in DCM, regardless of TTNtv status. This
data is important as we begin to understand multi-
modality risk stratiﬁcation in DCM (25).
FEWER ADVERSE OUTCOMES IN DCM AS COMPARED
WITH REGISTRY STUDIES. Finally, we found that the
rate of adverse events in this cohort, particularly
sudden cardiac death, is much lower than previous
registry data (12.9% in this study compared with 21%
in a registry substudy of 220 asymptomatic DCM pa-
tients) (18). Historic experience from our own insti-
tution (5,19) is also in line with previous registry data,
suggesting that our current ﬁndings are not simply a
reﬂection of CMR bias. Optimal medical therapy in
this study was in line with previously published co-
horts, with over 70% of patients on beta-blocker
therapy and almost 80% on angiotensin-converting
enzyme inhibitor treatment (5,18).
STUDY STRENGTHS. To date, studies evaluating ge-
notype–phenotype correlations in TTNtv DCM have
differed in the presence and extent of phenotypic
differences, as well as the clinical course of DCM, in
patients with and without TTNtv (6–9). In this study,
the largest to date, we mitigate the limitations of
these previous studies by using in-depth phenotyping
by CMR combined with longer follow-up, and inde-
pendently adjudicated clinical outcomes. This is a
representative DCM cohort with respect to age, sex,
and frequency of TTNtv, and the outcome predictors
identiﬁed are in line with established predictors of
outcome in DCM.
STUDY LIMITATIONS. This is a single-center study,
which introduces the possibility of referral bias.
However, as a major regional center for CMR, patients
were initially referred from over 30 regional district
general hospitals, alongside consecutive referrals
from a dedicated Inherited Cardiomyopathy Service,
in which CMR is performed routinely in all patients
without contraindication. This broad referral base
should mitigate bias.
The low arrhythmic event rate in this cohort may
reﬂect a CMR bias, with exclusion of patients from
other institutions who may not have had a CMR prior
to implantable cardiac-deﬁbrillator implantation. It
is, however, possible that previous estimates of
arrhythmic risk in DCM were conﬂated by inadvertent
TABLE 4 Baseline Cox Proportional Hazard Model Predicting the Primary Endpoint
Unadjusted Analysis Adjusted Analysis
HR 95% CI p Value HR 95% CI p Value
Left ventricular ejection
fraction, per 10%
0.70 0.57–0.81 <0.0001 0.70 0.58–0.84 0.0002
Indexed left atrial volume,
per 10 ml/m2
1.11 1.07–1.16 <0.0001 1.11 1.06–1.17 0.00001
Midwall ﬁbrosis late-gadolinium
enhancement present
2.39 1.53–3.74 0.0001 2.26 1.41–3.64 0.0008
Sustained ventricular
tachycardia present
4.70 2.04–10.85 0.0003 3.24 1.28–8.24 0.01
CI ¼ conﬁdence interval; HR ¼ hazard ratio.
FIGURE 5 Survival Curves Comparing Freedom From the Primary Endpoint in Patients
With and Without TTNtv
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Curves are compared using the log-rank test. Conﬁdence intervals are shown as dashed
lines. Follow-up time is shown as years since study enrollment. There is no signiﬁcant
difference between the 2 groups for the primary endpoint on unadjusted analysis.
TTNtv ¼ truncating variants in the titin gene.
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inclusion of patients with ischemic heart disease into
echocardiography-based studies, which has been
avoided through careful CMR-based phenotyping in
this cohort.
These ﬁndings require replication in an indepen-
dent cohort. At present, this is the largest published
cohort of patients with DCM who have undergone
CMR, genetic sequencing, and adjudicated long-term
follow-up. However, the number of events within this
cohort was not sufﬁcient to show an effect of TTNtv
on outcomes in DCM patients. With larger, multi-
center studies and longer-term follow-up, the effects
of TTNtv on clinical outcome may become more
apparent.
CONCLUSIONS
In this study, we identiﬁed distinct cardiac endo-
phenotypes of TTNtv DCM that may offer mecha-
nistic insights into the pathogenesis of DCM. We
also found that the clinical outcome in TTNtv DCM
is similar to patients without TTNtv DCM in a
cohort of patients with mild to moderate disease.
We note that the prevalence of TTNtv in severe
disease in transplant-listed cases can be as high as
20%, almost double that in the current study, which
remains unexplained. In summary, although TTNtv
are common in DCM and may be used to conﬁrm a
genetic cause for DCM and for cascade screening,
they do not appear to predict clinical outcomes in
ambulant DCM cases with medium-term (w4 year)
follow-up.
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Truncating variants in the titin gene (TTNtv) are the largest single genetic contributor to dilated cardiomyopathy (DCM). In this large, prospective,
genotype-phenotype study of ambulatory DCM patients, we show that prognostic indicators for all-cause DCM also predict outcomes in TTNtv DCM, and
that TTNtv DCM does not appear to be associated with a substantially worse medium-term prognosis, despite patients presenting at a younger age.
CVS ¼ cardiovascular; MRI ¼ magnetic resonance imaging.
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APPENDIX For an expanded Methods section
as well as supplemental tables and ﬁgures,
please see the online version of this article.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: TTNtv
are the largest single genetic contributor to DCM. In
ambulatory patients with DCM, TTNtv are associated with
a blunted hypertrophic response but do not carry an
increased risk of arrhythmias, heart failure, or death over
a period of nearly 4 years.
TRANSLATIONAL OUTLOOK: Further studies are
needed to deﬁne the mechanisms by which TTNtv affect
outcomes in patients with DCM and to assess their impact
on higher risk patients over longer-term follow-up.
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